An Open-Label, Randomized Phase II Trial of Personalized Peptide Vaccination in Patients with Bladder Cancer that Progressed after Platinum-Based Chemotherapy-Reference-Cited by-同舟云学术

An Open-Label, Randomized Phase II Trial of Personalized Peptide Vaccination in Patients with Bladder Cancer that Progressed after Platinum-Based Chemotherapy

Published:2015-11-18 Issue:1 Volume:22 Page:54-60
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Noguchi Masanori,Matsumoto Kazumasa,Uemura Hirotsugu,Arai Gaku,Eto Masatoshi,Naito Seiji,Ohyama Chikara,Nasu Yasutomo,Tanaka Masatoshi,Moriya Fukuko,Suekane Shigetaka,Matsueda Satoko,Komatsu Nobukazu,Sasada Tetsuro,Yamada Akira,Kakuma Tatsuyuki,Itoh Kyogo

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Vaccine approaches to treat urothelial cancer;Human Vaccines & Immunotherapeutics;2024-07-23

2. The bright side of chemistry: Exploring synthetic peptide‐based anticancer vaccines;Journal of Peptide Science;2024-04-03

3. A Comprehensive Review of Immunotherapy Clinical Trials for Metastatic Urothelial Carcinoma: Immune Checkpoint Inhibitors Alone or in Combination, Novel Antibodies, Cellular Therapies, and Vaccines;Cancers;2024-01-12

4. TAS0313 plus Pembrolizumab for Post-Chemotherapy Immune Checkpoint Inhibitor—Naïve Locally Advanced or Metastatic Urothelial Carcinoma;Molecular Cancer Therapeutics;2024-01-11

5. Metastatic Organotropism Differential Treatment Response in Urothelial Carcinoma: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials;European Urology Oncology;2023-11